Work

Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)

Year: 2012

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2011.36.1709

Authors: Jin Soo Lee, Vera Hirsh, Keunchil Park, Shukui Qin, Cesar R. Blajman, Reury-Perng Perng, Yuh-Min Chen, Laura Emerson, Peter Langmuir, Christian Manegold

Institutions: McGill University Health Centre, Samsung Medical Center, National Cancer Center, Sungkyunkwan University

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1978111504

FWCI: 33.81

Cites: 26

Cited by: 233

Related to: 10